Executive Summary
Across 23 8-K filings from April 13, 2026, focused on USA boardroom changes, a net positive trend emerges with 14 positive sentiment events (board expansions, experienced hires) outpacing 3 negative (sudden resignations) and 6 neutral, signaling proactive leadership refreshes amid 2026 economic pressures. CFO turnover dominates with 9 changes/appointments (e.g., Net Power, AdvanSix, CG Oncology, Commvault, AeroVironment), often with interim bridges and retention incentives like $420K salaries + RSUs, reflecting stabilization efforts. Biotech/pharma sector leads with 7 filings (e.g., Solana CMO exit, ALX CDOO hire for 12-18 month catalysts), while consumer/food sees high-materiality CEO shifts (Conagra 10/10). No broad period-over-period financial declines reported; instead, equity plan expansions (Xenon +30.6% shares) and reaffirmed guidance (Commvault FY2026) indicate capital allocation toward talent retention over buybacks/dividends. Portfolio implication: overweight firms with growth-aligned hires (e.g., Webtoon restructuring for 160M MAUs); monitor CEO voids like TVA for succession risks. Overall, 70% of changes expand expertise in transformation/AI/power markets, positioning for outperformance vs. stagnant peers.
Tracking the trend? Catch up on the prior US Corporate Board Director Changes SEC Filings digest from April 06, 2026.
Investment Signals(11)
- WEBTOON Entertainment↓(BULLISH)▲
Leadership restructure eliminates COO/CTO, elevates AI Head and creates Chief Business Officer for 160M MAU ecosystem growth, effective Apr 13
- COMMERCIAL METALS↓(BULLISH)▲
Appointed transformation expert Mike Dumais (ex-Raytheon EVP) to board expanding to 10 directors, aligning with operational excellence priorities
- JACK IN THE BOX↓(BULLISH)▲
Added 30+ yr restaurant exec Eduardo Luz as director amid board refresh (2 retirements), targeting same-store sales/debt reduction
- ProFrac Holding↓(BULLISH)▲
Granted PSUs (287.5K to Exec Chair/CEO, 270K to CFO) with $7-18 VWAP vesting + $1M CFO cash incentive through 2026 for retention
- AdvanSix↓(BULLISH)▲
Named Patrick Day (ex-FMC VP FP&A) as permanent CFO effective Apr 27, succeeding interim, to drive growth/value creation
- CONAGRA BRANDS↓(BULLISH)▲
Appointed John Brase (ex-Smucker $6B biz leader) as CEO/President/Director effective Jun 1, succeeding Connolly post-$12B FY25 sales transformation
- COMMVAULT SYSTEMS↓(BULLISH)▲
Reappointed insider Gary Merrill as CFO + Geoff Haydon as Pres Customer Ops, reaffirmed Q4/FY2026 guidance unchanged from Jan 27
- AeroVironment↓(BULLISH)▲
Promoted internal 15-yr vet Sean Woodward to CFO effective May 1, crediting $10B mkt cap growth, smooth transition via advisory
- CG Oncology↓(BULLISH)▲
Permanent CFO Jim DeTore (ex-Neurogastrx/Bluebird) with $520K base + $5M equity target, PSUs tied to product launch/cash flow
- ALX ONCOLOGY↓(BULLISH)▲
Hired 30+ yr biopharma vet Jeff Knight as CDOO for evorpacept/ALX2004 catalysts in next 12-18 months
- HUDSON TECHNOLOGIES↓(BULLISH)▲
Added capital markets (Alan Sheriff ex-PNC) + ops (Jeffrey Feeler ex-US Ecology CEO) directors post-30 yr vet resignation
Risk Flags(7)
- Tennessee Valley Authority/CEO Departure↓[HIGH RISK]▼
CEO Donald Moul separation Apr 7 with severance, no reasons/successor disclosed, high materiality 9/10
- Solana Co/CMO Resignation↓[HIGH RISK]▼
Sudden mutual separation of CMO Antonella Favit-Van Pelt Apr 8, $875K lump sum payout, no successor named
- Mobile Global Esports/CFO Resignation↓[HIGH RISK]▼
CFO Consultant Mark Keeley resigned Apr 9, CEO Brett Rosin interim principal accounting officer, no reasons/compensation
- FEDEX CORP/CFO Transition↓[MEDIUM RISK]▼
EVP/CFO John Dietrich steps down Jun 1 (departs Jul 31), interim Claude Russ with added duties/search ongoing, no disagreement noted
- INDEPENDENT BANK CORP/Director Retirement↓[MEDIUM RISK]▼
Mary Lentz retired Apr 11 at mandatory age 72, Audit/Risk Committee vacancy per governance rules
- JACK IN THE BOX/Board Retirements↓[MEDIUM RISK]▼
David Goebel/Madeleine Kleiner retire May 8 amid shareholder feedback on sales/debt/margins
- ▼
Vincent Abbatecola resigned Apr 10 after 30+ years, though offset by 2 new adds
Opportunities(8)
- CONAGRA BRANDS/CEO Transition↓(OPPORTUNITY)◆
Brase's 35+ yr CPG experience (Smucker/P&G) positions for $12B sales acceleration post-Connolly, materiality 10/10
- WEBTOON Entertainment/Restructuring↓(OPPORTUNITY)◆
Unified ops under Pres Kim with AI/IP focus for 160M MAUs, eliminates redundancies for growth alpha
- ProFrac Holding/Exec Retention↓(OPPORTUNITY)◆
PSU vesting at $7-18 VWAP + $1M CFO cash signals undervalued stock if below thresholds, talent lock-in
- Commvault/Guidance + Leadership↓(OPPORTUNITY)◆
Reaffirmed FY2026 guidance + insider CFO return supports SaaS/subscription growth, earnings Apr 28
- ALX ONCOLOGY/CDOO Hire↓(OPPORTUNITY)◆
Knight's expertise targets 12-18 mo clinical catalysts for evorpacept/ALX2004, biopharma pipeline alpha
- CG Oncology/CFO Permanency↓(OPPORTUNITY)◆
DeTore's biotech CFO track record + launch-tied PSUs positions for commercialization inflection
- AeroVironment/Internal CFO Promo↓(OPPORTUNITY)◆
Woodward's 15-yr role in $10B mkt cap growth + defense tech commercialization continuity
- AdvanSix/CFO Upgrade↓(OPPORTUNITY)◆
Day's FP&A/IR experience from FMC strengthens chem sector growth vs. interim Gramm
Sector Themes(5)
- CFO Turnover Surge in Mid/Small Caps◆
9/23 filings (39%) involve CFO changes/appointments (Net Power, AdvanSix, CG Oncology, etc.), often internal/promotions with equity incentives, signaling finance stabilization for 2026 capex/growth vs. large caps stable
- Biotech/Pharma Talent Push◆
7/23 (30%) filings with CMO/CDOO/CFO/dir adds (Solana exit offset by ALX/Palvella/CG/Vistagen), retention options/PSUs common, tied to 12-18 mo catalysts amid clinical risks
- Board Refresh/Expansion Wave◆
10/23 (43%) add directors (CMC, Jack in Box, Palvella, Navitas, Dario, Hudson), avg +1 size, bringing 30-40 yr expertise in transformation/AI/power, responsive to shareholders
- Retention Incentives Over Cash◆
Equity grants dominate (Xenon +30.6% shares, ProFrac PSUs, Vistagen opts for all employees, Mirion perf options), no dividend/buyback shifts, prioritizing talent amid no YoY financial declines noted
- Consumer/Food Leadership Overhaul◆
High materiality CEO/dir shifts (Conagra 10/10, Jack in Box 7/10) with restaurant/CPG vets targeting margins/sales, contrasting neutral utility/bank retirements
Watch List(8)
Monitor Jun 1 transition impact on $12B sales guidance, potential Q2 update [Jun 1, 2026]
Interim Russ starts Jun 1, separation agreement details in 8-K amend (within 4 days), successor announcement [Jun 1, 2026]
Reaffirmed guidance discussion, leadership impact on SaaS growth [Apr 28, 2026]
- TVA/CEO Succession👁
No successor post-Moul separation, watch for 8-K on interim/permanent CEO [Ongoing post-Apr 13]
Track stock VWAP vs. $7-18 thresholds for exec retention through Apr 2027 [Apr 7, 2027]
Knight hire supports evorpacept/ALX2004 milestones [Next 12-18 months]
Post-May 8 size reduction to 9, assess transformation progress in Q2 earnings [May 8, 2026]
Interim CEO as accounting officer, watch for permanent CFO 8-K [Post-Apr 9, 2026]
Filing Analyses(23)
13-04-2026
Effective April 11, 2026, Mary L. Lentz retired from the Board of Directors of Independent Bank Corp. and Rockland Trust Company upon reaching the age of 72, in accordance with the company's Governance Principles mandating retirement at that age. She had served as a Director since 2016, a member of the Audit Committee since 2018, and the Risk Committee since 2024. The filing includes no financial impacts or other changes.
- ·Governance Principles require directors to retire upon attaining age 72
- ·Filing signed by Patricia M. Natale on April 13, 2026
13-04-2026
On April 7, 2026, Xenon Pharmaceuticals Inc. amended and restated its 2025 Inducement Equity Incentive Plan, increasing the maximum number of common shares reserved for issuance from 900,000 to 1,175,000 shares (a 30.6% increase). The plan is exclusively for inducement grants such as nonstatutory stock options, stock appreciation rights, restricted stock units, restricted stock, and performance awards to new hires or rehired employees following a bona fide interruption. No shareholder approval was sought, in accordance with Nasdaq Listing Rule 5635(c)(4).
- ·Filing date: April 13, 2026
- ·Exhibit 10.1: Amended and Restated 2025 Inducement Plan and related form agreements filed
- ·Plan amendments subject to adjustments as provided therein
13-04-2026
WEBTOON Entertainment Inc. (Nasdaq: WBTN) announced a restructured global leadership team under President Yongsoo Kim to accelerate growth, eliminating the Chief Operating Officer and Chief Technology Officer roles while creating a new Chief Business Officer position led by Leah Goeun Yeon. Key elevations include Yuki Chae to Chief Product Officer, Teo Taeyeong Jang to Head of AI, and Sean Shinhyung Kim to Head of IP Business; David J Lee will add President of Wattpad to his CFO duties. The changes unify operations across WEBTOON's ecosystem, which serves approximately 160 million monthly active users.
- ·Leadership changes effective as of April 13, 2026 filing date.
- ·All new roles report directly to President Yongsoo Kim, except David J Lee who reports to CEO Junkoo Kim as CFO.
- ·Chief Business Officer oversees growth, marketing, content, and creator management for Korean and Rest of World webcomic platform (excluding Japan).
13-04-2026
CMC announced the appointment of Michael “Mike” Dumais to its Board of Directors, effective June 23, 2026, increasing the board from nine to ten directors, with nine independent. Mr. Dumais brings over 30 years of leadership experience, most recently as Executive Vice President and Chief Transformation Officer at Raytheon Technologies Corporation, and previously in senior roles at United Technologies Corporation; he will serve on the Audit and Finance Committees. Chairman Robert S. Wetherbee and CEO Peter Matt highlighted his alignment with CMC's strategic priorities in operational excellence and growth.
- ·Mr. Dumais serves on the board of directors at Baker Hughes Company.
- ·Mr. Dumais earned a Bachelor of Science in Electrical Engineering from Virginia Tech, a Master of Science in Electrical Engineering from the University of Pennsylvania, and a Master of Business Administration from the Wharton School of the University of Pennsylvania.
- ·CMC is a Fortune 500 company headquartered in Irving, Texas, founded in 1915.
13-04-2026
Jack in the Box Inc. appointed Eduardo Luz, an experienced restaurant executive formerly CEO of P.F. Chang’s, as an independent director to support the company's transformation and board refreshment. David Goebel and Madeleine Kleiner will retire from the Board effective May 8, 2026, reducing its size to nine members. The changes reflect responsiveness to shareholder feedback amid efforts to drive same-store sales, reduce debt, and improve margins.
- ·Eduardo Luz has over 30 years of experience in restaurant and consumer goods industries.
- ·Appointment announced on April 13, 2026; retirements effective May 8, 2026.
- ·Board refreshment ongoing to align with evolving business needs.
13-04-2026
Net Power Inc. appointed Ned Leland (Lee) Shuman as Chief Financial Officer effective April 13, 2026, replacing interim CFO Daniel J. Rice IV, who will remain CEO and serve as principal financial officer until the Q1 2026 10-Q filing. Mr. Shuman brings over 25 years of experience, including leading $1.6B in financings at WattBridge Energy for a 2.4 GW portfolio. Compensation includes $420,000 base salary, 60% STIP target bonus, 180% LTIP target, $800,000 RSU grant vesting over three years, and $100,000 cash bonus.
- ·Mr. Shuman previously served as Head of Power Finance at Javelin Global Commodities (April 2024-April 2026) and CFO of WattBridge Energy (2020-April 2024).
- ·No family relationships or special understandings regarding Mr. Shuman's selection.
- ·Mr. Shuman holds J.D. from University of Georgia, M.Tax and M.B.A. from Georgia State University, B.A. from Emory University.
13-04-2026
Solana Company announced on April 8, 2026, the mutual separation and resignation of its Chief Medical Officer, Antonella Favit-Van Pelt, MD, PhD, effective immediately. Under the separation agreement, the Company will pay Dr. Favit-Van Pelt a lump sum of $875,000 within ten business days, less withholdings, in exchange for a release of claims and ongoing compliance with confidentiality and invention assignment obligations. No successor has been named in the filing.
- ·Separation Agreement filed as Exhibit 10.1
- ·Report date: April 8, 2026; Filing date: April 13, 2026
- ·Company address: 642 Newtown Yardley Road, Suite 100, Newtown, PA 18940
13-04-2026
On April 7, 2026, ProFrac Holding Corp.'s Compensation Committee granted performance-based restricted stock unit (PSU) awards under the 2022 Long Term Incentive Plan to key executives: 287,500 PSUs each to Executive Chairman Matthew D. Wilks and CEO Johnathan L. Wilks, 270,000 PSUs to CFO Austin Harbour, and 150,000 PSUs to Chief Commercial Officer Matthew Greenwood, vesting subject to one-year service and stock price VWAP thresholds of $7-$18. Additionally, CFO Harbour received a special $1,000,000 cash incentive award payable in four $250,000 quarterly installments through December 31, 2026, subject to continued employment. No performance declines or negative metrics reported; awards aim to retain executive talent.
- ·PSUs require continuous employment through April 7, 2027 (Time-Based Vesting Date); unvested PSUs expire April 7, 2036, with negotiation for new incentives.
- ·CFO cash award first installment vested as of March 31, 2026; includes forfeiture and repayment clauses for voluntary termination or termination for Cause in 2026.
- ·VWAP measured over most recent 30 trading days; settlement within 30 days of vesting.
13-04-2026
On April 7, 2026, the Compensation Committee of Vistagen Therapeutics, Inc. approved retention awards in the form of stock options to all company employees, including five key executives each receiving options to purchase 75,000 shares of common stock at an exercise price of $0.5358 per share. The options, granted under the Amended and Restated 2019 Omnibus Equity Incentive Plan, vest with 25% vesting six months after the grant date and the remainder in additional 25% installments every six months thereafter, becoming fully vested on the two-year anniversary. No departures, elections, or appointments of directors or officers were reported.
13-04-2026
On April 9, 2026, Mark Keeley resigned as Chief Financial Officer Consultant of Mobile Global Esports, Inc. Brett Rosin, the Company's Chief Executive Officer, will serve as the principal accounting officer on an interim basis until a new Chief Financial Officer is hired. The filing discloses no details on the reasons for the resignation or any compensatory arrangements.
- ·Company trades as MGAM on OTC Pink Sheets
- ·Emerging growth company status confirmed
- ·Principal executive offices: 500 Post Road East, 2nd Floor, Westport, CT 06883
13-04-2026
AdvanSix Inc. (NYSE: ASIX) announced the appointment of Patrick C. Day as Senior Vice President and Chief Financial Officer, effective April 27, 2026, reporting to President and CEO Erin Kane. Day, previously VP of Financial Planning and Analysis and Investor Relations at FMC Corporation, replaces interim CFO Christopher Gramm, who will continue as Vice President of Corporate Finance and Strategic Financial Planning & Analysis. The appointment is positioned as strengthening leadership for growth and value creation.
- ·Filing Date: April 13, 2026
- ·Appointment effective: April 27, 2026
- ·Day's education: Bachelor’s degree in finance from Elizabethtown College; Master’s degree in accounting and tax from the University of Connecticut
13-04-2026
Conagra Brands, Inc. (NYSE: CAG) announced the appointment of John Brase as President and Chief Executive Officer effective June 1, 2026, succeeding Sean Connolly who will step down from his leadership roles and the Board on May 31, 2026. Brase, with over 35 years of experience including roles at The J.M. Smucker Co. and Procter & Gamble where he led a $6B business, will also join the Board. The transition is described as smooth, with praise for Connolly's decade-long leadership in transforming Conagra into a pure-play food company generating fiscal 2025 net sales of nearly $12B.
- ·Brase previously oversaw U.S. retail, international, and Away from Home businesses at Smucker
- ·Conagra headquartered in Chicago
- ·Media contact: Mike Cummins (312-549-5257)
- ·Investor contact: Matthew Neisius (402-240-3226)
13-04-2026
Palvella Therapeutics, Inc. increased its Board of Directors from six to seven members and appointed John Doux, M.D., as a Class III director effective April 13, 2026, with term expiring at the 2026 Annual Meeting of Stockholders. Dr. Doux, a board-certified dermatologist with extensive experience in healthcare investments and prior service on the Company's board pre-reverse merger, was granted an option to purchase 6,000 shares of common stock vesting over 36 months per the Director Compensation Policy. The Board determined Dr. Doux to be independent under Nasdaq rules, with no related party transactions or family relationships.
- ·Dr. Doux, age 57, previously served on the Company's board from 2019 to 2022 prior to its reverse merger.
- ·No arrangements or understandings pursuant to which Dr. Doux was selected as director.
- ·Dr. Doux served on boards of multiple biotechnology companies, including Ceptaris Therapeutics acquired by Actelion.
13-04-2026
FedEx Corporation announced that Executive Vice President and Chief Financial Officer John W. Dietrich will step down from his role on June 1, 2026, and fully depart the company on July 31, 2026, with no disagreement on financial or operational matters. The Board of Directors appointed Claude F. Russ, current Enterprise Vice President, Finance, as Interim Chief Financial Officer effective June 1, 2026, while he retains his existing responsibilities and the company conducts an internal and external search for a permanent successor. Russ will receive additional compensation of $25,000 per month and a one-time $50,000 restricted stock unit award vesting over three years.
- ·John W. Dietrich’s departure is not due to any disagreement with the Company on financial controls, statements, operations, policies, or practices.
- ·FedEx and Mr. Dietrich expect to enter a separation and release agreement; details to be filed in an amendment to this 8-K within four business days of determination.
- ·Claude F. Russ has served in various FedEx roles since 2002, including Senior Vice President and CFO of FedEx Freight, and President/CEO of FedEx Dataworks.
- ·No family relationship between Claude F. Russ and any director or executive officer; no related transactions under Item 404(a) of Regulation S-K.
13-04-2026
Mirion Technologies, Inc. entered into a Performance Stock Option Award Agreement with Thomas D. Logan on April 9, 2026, granting him performance stock options to purchase shares of Class A Common Stock, subject to service and performance conditions detailed in an attached Awards Summary Schedule (not provided). The options are divided into Tranche I (measurable at third anniversary of grant) and Tranche II (fourth anniversary), with payouts ranging from 0% to 150% of target based on performance relative to peers, and include pro-rata vesting for certain terminations post-Tranche I but forfeiture for cause. No specific target or maximum option counts, exercise price, or performance metrics are detailed in the filing excerpt.
- ·Pro Rata Amount denominator: 1,460 days (approx. 4 years)
- ·Expiration: earliest of termination for Cause or 7th anniversary of grant date
- ·Post-vest share sale restriction: 1 year
- ·CIC measurement: 60 trading days prior to 2 days before CIC Date
- ·Employment Agreement reference: August 13, 2021 (as amended)
13-04-2026
CG Oncology, Inc. appointed Jim DeTore, age 61, as Chief Financial Officer effective April 13, 2026, transitioning from his role as Interim Principal Financial and Accounting Officer since November 2025. Under the employment agreement, Mr. DeTore receives an initial annual base salary of $520,000, target annual bonus of 45% of base salary, initial stock option award with $4 million target value, and PSU award with $1 million target value, both granting on April 15, 2026. No other material changes or concerns such as family relationships or related-party transactions were reported.
- ·Stock options vest 25% after 12 months from April 13, 2026, then 36 equal monthly installments; PSUs vest 30% on first U.S. commercial sale of Company's first approved product and 70% on positive operating cash flow for two consecutive fiscal quarters post-launch.
- ·Severance includes 12 months base salary, prorated bonus, COBRA up to 12 months, and 12-month equity acceleration outside change-in-control; 1.5x base, full bonus, COBRA up to 18 months, full equity acceleration within change-in-control.
- ·Prior experience: CFO at Neurogastrx (June 2021-June 2025), independent CFO consultant to biotech/pharma (March 2017-May 2021), CFO at Proteostasis (Aug 2016-Feb 2017), CFO at Bluebird Bio (Nov 2014-Feb 2016).
- ·Company's principal executive offices now at 3000 Pegasus Park Drive, Suite 1640, Dallas, Texas 75247 (former: 400 Spectrum Center Drive, Suite 2040, Irvine, CA 92618).
13-04-2026
DarioHealth Corp. (NASDAQ: DRIO) announced the appointment of John R. Palumbo, a healthcare executive with over 40 years of experience including senior roles at AmerisourceBergen Corporation (now Cencora, Inc.) and Allscripts Healthcare Solutions, Inc. (now Veradigm, Inc.), to its Board of Directors on April 13, 2026. The appointment aims to support Dario's commercial scaling through partnerships with health systems and payers. CEO Erez Raphael emphasized Palumbo's strategic insight, operational expertise, and industry relationships to accelerate growth and value realization.
- ·Palumbo currently serves on boards of PM Pediatrics Management Group, LLC, Lucid Diagnostics Inc., ivWatch, LLC, and Qless, Inc., and chairs the advisory board of Brado Cuneo Nollau, LLC.
- ·Dario provides solutions for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health to health plans, employers, providers, and consumers.
13-04-2026
ALX Oncology Holdings Inc. (Nasdaq: ALXO) appointed Jeff Knight, M.P.H., as Chief Development and Operating Officer effective April 13, 2026, bringing over 30 years of biopharmaceutical experience from roles at Crinetics Pharmaceuticals, Poseida Therapeutics, Halozyme Therapeutics, Amgen, Onyx Pharmaceuticals, and Genentech. CEO Jason Lettmann highlighted Knight's expertise to support upcoming catalysts for evorpacept and ALX2004 clinical programs in the next 12-18 months. No financial impacts or performance metrics were disclosed.
- ·Appointment effective date: April 13, 2026
- ·Upcoming milestones timeframe: next 12 to 18 months
- ·Knight's education: Master of Public Health in Biostatistics and Epidemiology and Bachelor of Arts in Psychology from University of Oklahoma; Bachelor of Science in Nursing from University of Kansas
13-04-2026
Commvault announced two leadership appointments effective immediately: Gary Merrill as Chief Financial Officer (CFO), returning after serving in the role from 2022-2024 and most recently as Chief Commercial Officer, and Geoff Haydon as President of Customer and Field Operations, who is stepping down from the Board of Directors. Both report to President and CEO Sanjay Mirchandani, aiming to support growth in subscription/SaaS and customer operations. The company reaffirmed its fourth quarter and fiscal year 2026 guidance previously issued on January 27, 2026, with no changes indicated.
- ·Gary Merrill has over two decades at Commvault, including 15 years in finance.
- ·Next earnings conference call scheduled for April 28, 2026 at 8:30 a.m. EDT; webcast or dial-in (800) 715-9871 (toll-free) or (646) 307-1963 (international), event ID 5826149.
13-04-2026
Hudson Technologies, Inc. (NASDAQ: HDSN) announced the appointment of Alan Sheriff and Jeffrey Feeler as independent directors effective April 13, 2026, bringing 40 years of capital markets expertise and over 30 years of operational experience in recycling and environmental services, respectively, to support strategic growth initiatives. The board accepted the resignation of Vincent Abbatecola effective April 10, 2026, after more than three decades of service. CEO Ken Gaglione praised the new directors' expertise and expressed gratitude for Abbatecola's foundational contributions.
- ·Alan Sheriff previously served as Vice Chairman of PNC Financial Services Group's Corporate & Institutional Bank and founded Solebury Capital.
- ·Jeffrey Feeler led US Ecology Inc. from 2006, becoming Chairman and CEO in 2013 until its 2022 sale.
- ·Filing items: 5.02 (Director/Officer Departure/Election), 7.01, 9.01.
13-04-2026
AeroVironment, Inc. (AVAV) announced the appointment of Sean T. Woodward as Executive Vice President and Chief Financial Officer, effective May 1, 2026, succeeding Kevin McDonnell, who will remain in an advisory role through July 2026 to ensure a smooth transition. Woodward, with over 22 years of experience in defense technology including 15 years at AV, most recently served as CFO of AV's Autonomous Systems (AxS) segment and has contributed to the company's growth to roughly $10 billion market cap. CEO Wahid Nawabi praised Woodward's institutional knowledge and role in commercializing high-growth products.
- ·Appointment effective May 1, 2026
- ·McDonnell advisory role through July 2026
- ·Woodward holds BS in business management from University of South Florida and MBA in Finance from University of Tampa
- ·Investor contact: Denise Pacioni (ir@avinc.com, 805.795.4108)
- ·Media contact: BJ Koubaroulis (bj.koubaroulis@avinc.com, 747.324.5358)
Get daily alerts with 11 investment signals, 7 risk alerts, 8 opportunities and full AI analysis of all 23 filings
🇺🇸 More from United States
View all →April 06, 2026
US Pre-Market SEC Filings Roundup — April 06, 2026
US Pre-Market SEC Filings Roundup
April 06, 2026
US Merger & Acquisition SEC Filings — April 06, 2026
US Merger & Acquisition SEC Filings
April 06, 2026
US IPO Pipeline SEC S-1 Filings — April 06, 2026
US IPO Pipeline SEC S-1 Filings
April 06, 2026
US Executive Officer Management Changes SEC — April 06, 2026
US Executive Officer Management Changes SEC